Senores Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about Senores Pharmaceuticals

Senores Pharma Grants ₹15 Cr Loan to Apnar Pharma 3 days ago

Senores Pharmaceuticals has entered into a loan agreement with Apnar Pharma Private Limited for an unsecured inter-corporate loan of up to ₹15 crores. The loan carries an interest rate of 10% per annum and is repayable on demand. An initial amount of ₹1 crore has been disbursed. The loan is intended for Apnar Pharma to discharge and pay off liabilities. Both companies have confirmed they are not related to each other.

Senores Pharmaceuticals: New Plant Expected to Generate ₹100-120Cr Revenue 7 days ago

Senores Pharma Acquires Apnar Pharma in Deal Worth ₹91 Crores 8 days ago

Senores Pharmaceuticals Launches Deferiprone Tablets in US Through Dr. Reddy's Partnership Dec 11, 2025

Senores Pharmaceuticals Limited: Promoter Group Pledges Shares Dec 05, 2025

More news about Senores Pharmaceuticals

13Nov 25

Senores Pharmaceuticals Reports Strong Q2 FY26 Growth, Maintains Annual Guidance

Senores Pharmaceuticals Limited announced robust Q2 FY26 results, with consolidated income up 61% to INR 162.00 crores. EBITDA reached INR 50.00 crores with margins improving to 31%. PAT grew 131% to INR 30.00 crores. Regulated markets revenue increased 87%, while emerging markets grew 9% sequentially. The company expanded its product portfolio, received new approvals, and reaffirmed its FY26 guidance of at least 50% top-line growth and 100% PAT growth. Senores acquired a 51% stake in Zoraya Pharmaceuticals LLC and is progressing with its API manufacturing facility.

07Nov 25

Senores Pharmaceuticals Reports Strong Q2 FY26 Performance with 131% PAT Growth

Senores Pharmaceuticals announced robust financial results for Q2 and H1 FY26. Q2 highlights include 61% revenue growth to Rs. 162.00 crores, 113% EBITDA increase to Rs. 50.00 crores, and 131% PAT growth to Rs. 30.00 crores. H1 FY26 saw revenue rise by 66% to Rs. 300.00 crores, EBITDA expand by 88% to Rs. 84.00 crores, and PAT increase by 114% to Rs. 51.00 crores. Regulated Markets segment showed strong performance with improved EBITDA margins. The company launched eight new products in Regulated Markets during Q2 and generated Rs. 31.40 crore in operating cash flow for H1 FY26. Management expects continued growth momentum in the Own Products business through H2 and FY27.

06Nov 25

Senores Pharmaceuticals Reports Strong Q2 Performance with 61% Revenue Growth and Senior Management Appointment

Senores Pharmaceuticals announced impressive Q2 FY26 results, with consolidated revenue up 61% YoY to Rs. 162.00 crores and profit after tax surging 131% YoY to Rs. 30.00 crores. Half-year performance showed 66% revenue growth to Rs. 300.00 crores and 114% increase in profit after tax to Rs. 51.00 crores. The company's growth was driven by strong performance in regulated markets (87% YoY growth) and branded generics (over 10x YoY increase). Operating cash flow for H1 was Rs. 31.40 crores. The board approved the appointment of Mr. Manohar Lalge as President-Research and Development, effective November 6, 2025.

05Nov 25

Senores Pharmaceuticals' US Subsidiary Receives FDA Clearance After Addressing Minor Observations

Senores Pharmaceuticals' subsidiary, Havix Group Inc., has resolved all FDA observations and received an Establishment Inspection Report for its Georgia facility. The company also announced its subsidiary, Senores Pharmaceuticals, Inc., has acquired a 51% stake in Zoraya Pharmaceuticals, LLC, a newly formed entity in Delaware, expanding its presence in the US market.

05Nov 25

Senores Pharmaceuticals Expands into U.S. Market with New Subsidiary and Strategic Acquisition

Senores Pharmaceuticals has formed a wholly-owned U.S. subsidiary, Senores Pharmaceuticals, Inc. (SPI), which acquired a 51% stake in Delaware-based Zoraya Pharmaceuticals, LLC on November 04, 2025. This strategic move aims to strengthen Senores' presence in the U.S. pharmaceutical market. Additionally, Senores' material subsidiary, Havix Group Inc., received an Establishment Inspection Report from the USFDA on November 04, 2025, resolving minor observations from a July inspection of its Georgia facility.

18Sept 25

Senores Pharmaceuticals Invests $2M in US Subsidiary for Expansion

Senores Pharmaceuticals Limited has invested $2 million (₹16.6 crore) in its US subsidiary, Senores Pharmaceuticals Inc. (SPI), through a rights issue of 120,480 equity shares at $16.60 per share. The investment aligns with the company's IPO proceeds utilization plan and aims to strengthen its presence in the American market. SPI, incorporated in 2021, manages intellectual properties, ANDA approvals, and marketing partnerships in the US. The subsidiary has shown significant growth, with turnover increasing from $3.35 million in March 2023 to $11.41 million in March 2025. The investment complies with FEMA and SEBI regulations and is expected to enhance working capital, support IP portfolio growth, and strengthen US marketing partnerships.

12Sept 25

Senores Pharmaceuticals Completes Acquisition of Havix Group Inc. Shares

Senores Pharmaceuticals Limited has finalized its acquisition of 8,454 equity shares in Havix Group Inc. (Aavis Pharmaceuticals). The acquisition was executed in two phases: 7,914 shares acquired directly and 540 shares through its US subsidiary, Senores Pharmaceuticals Inc. The phased approach was due to regulatory requirements from the Reserve Bank of India. The transaction, which began in March 2025, has now been completed as confirmed by the company's Company Secretary and Compliance Officer, Vinay Kumar Mishra.

28Jul 25

Havix, Subsidiary of Senores Pharmaceuticals, Completes USFDA Inspection with 3 Minor Observations

Senores Pharmaceuticals' subsidiary, Havix Group Inc., completed a USFDA inspection at its Hoschton, Georgia facility from July 21-25, 2025. The inspection resulted in three Form 483 observations, described as procedural and minor. Havix has 15 days to respond to these observations and intends to address them within the given timeframe.

23Jul 25

Senores Pharmaceuticals Reports 72% Revenue Growth in Q1FY26 with Strong Performance Across Segments

Senores Pharmaceuticals announced strong Q1 FY26 results with consolidated total income of Rs 138.00 crores, up 72% year-on-year. EBITDA increased by 60% to Rs 34.20 crores, while PAT grew 95% to Rs 21.20 crores. Regulated markets contributed 65% of total revenue at Rs 90.10 crores. The company received ANDA approval for 4 products, commercialized 2, and launched 5 new products. Senores increased its stake in subsidiary Havix to 73% and reported positive operating cash flow of Rs 11.00 crores.

06Jun 25

SenoRes Pharma Eyes Multiple Government Contracts, Boosting Business Prospects

SenoRes Pharma, a major pharmaceutical company, is reportedly close to securing multiple government contracts according to NDTV Profit. This development could significantly boost the company's business outlook and market position. Government contracts in the pharmaceutical industry often provide stable revenue streams, enhance credibility, and may lead to increased production and investment in research and development. While specific details remain undisclosed, the market is expected to closely monitor SenoRes Pharma's performance in light of this news.

20May 25

Senores Pharmaceuticals Expands Portfolio with Acquisition of Enalapril Maleate ANDA

Senores Pharmaceuticals has acquired the Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets from Wockhardt, covering strengths of 2.5mg, 5mg, 10mg, and 20mg. The US market size for Enalapril tablets is estimated between USD 28.60 million (IQVIA data, MAT December 2024) and USD 109.24 million (Symphony data, MAT March 2025). Enalapril Maleate, an ACE inhibitor, is used to treat hypertension, congestive heart failure, and improve post-heart attack survival.

09May 25

Senores Pharmaceuticals Expands Portfolio with Tramadol ANDA Acquisition

Senores Pharmaceuticals has acquired the Abbreviated New Drug Application (ANDA) for Tramadol Tablets from APDM Pharmaceuticals. This strategic move allows Senores to manufacture and market generic Tramadol in the United States, strengthening its position in the U.S. generic drug market. The acquisition offers potential for market expansion, new revenue streams, and portfolio diversification for Senores in the competitive pharmaceutical landscape.

06May 25

Senores Pharmaceuticals Expands Portfolio with Acquisition of Topiramate ANDA from Wockhardt

Senores Pharmaceuticals Limited has acquired the ANDA for Topiramate HCl tablets from Wockhardt Limited through its US subsidiary. The acquisition includes FDA-approved tablets in four strengths, targeting a $111.47 million market as of December 2024. Funded by IPO proceeds, this move aligns with the company's strategic objectives and strengthens its position in epilepsy and migraine treatments in the US market.

05May 25

Senores Pharmaceuticals Expands Portfolio with Acquisition of Topiramate ANDA

Senores Pharmaceuticals Limited (SPL) has acquired the Abbreviated New Drug Application (ANDA) for Topiramate HCl tablets from Wockhardt Limited on May 5, 2025. The acquisition covers tablet strengths of 25, 50, 100, and 200 mg. The US market size for Topiramate tablets was approximately $111.47 million as of December 2024. The acquisition will be funded using IPO proceeds and aligns with SPL's strategy to expand in the US pharmaceutical market, particularly in neurology. SPL currently has 61 ANDAs, 22 CMO/CDMO commercial products in the USA, and over 260 product registrations in emerging markets.

12Mar 25

Senores Pharmaceuticals Strengthens Hold on Havix Group with 3.73% Stake Acquisition

Senores Pharmaceuticals Limited is set to acquire an additional 3.73% stake in its US-based subsidiary, Havix Group Inc. (Aavis Pharmaceuticals), for USD 1.35 million. This move will increase Senores' ownership from 51.23% to 54.96%. Havix Group, founded in 2015, has shown significant growth with its turnover rising from USD 7.34 million in FY2022 to USD 14.44 million in FY2024. The acquisition, subject to regulatory approvals, is expected to complete within 10 days of the Share Purchase Agreement execution.

11Mar 25

Senores Pharmaceuticals Boosts Stake in Havix Group, Strengthening Its US Presence

Senores Pharmaceuticals Limited plans to acquire an additional 3.73% stake in its US-based subsidiary, Havix Group Inc., increasing its ownership from 51.23% to 54.96%. The acquisition involves 8,454 equity shares at $160 per share, to be completed within 10 days of the share purchase agreement signed on March 11, 2025. Havix Group, specializing in finished formulations, has shown strong financial growth with its turnover nearly doubling from $7.3 million in FY 2022 to $14.4 million in FY 2024.

04Mar 25

Senores Pharmaceuticals Acquires 14 ANDAs from Dr. Reddy's, Eyes $421 Million US Market Opportunity

Senores Pharmaceuticals has acquired 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories, including 13 FDA-approved and 1 pending approval. The acquisition targets a US market opportunity of $421 million, with potential for $1.13 billion. The company will fund this using IPO proceeds. The acquired portfolio spans various therapeutic areas and includes controlled substances, enhancing Senores' product offerings in the US and other markets.

27Feb 25

Senores Pharmaceuticals Expands API Manufacturing with New Gujarat Facility

Senores Pharmaceuticals Limited has launched its second Active Pharmaceutical Ingredient (API) manufacturing facility in Rajpur, Kadi, Mehsana, Gujarat. The new greenfield plant, spanning 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, began operations on February 26, 2025. This strategic expansion aims to enhance the company's API manufacturing capabilities, broaden its product offerings, and strengthen its position in regulated markets, particularly in the CDMO/CMO business segment.

26Feb 25

Senores Pharmaceuticals Expands API Production with New Gujarat Facility

Senores Pharmaceuticals Limited has inaugurated its second Active Pharmaceutical Ingredient (API) manufacturing facility in Rajpur, Kadi, Mehsana, Gujarat. The new greenfield plant, spanning 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, commenced operations on February 26, 2025. This expansion is expected to enhance Senores' product offerings, competitiveness in regulated markets, and strengthen its position in the CDMO/CMO sector. The company, with existing operations in the US and India, views this as a strategic move to broaden its capabilities and market reach.

21Feb 25

Senores Pharmaceuticals Expands Portfolio with Roflumilast ANDA Acquisition

Senores Pharmaceuticals Limited (SPL) has acquired the ANDA for Roflumilast tablets from Breckenridge Pharmaceutical, Inc. The acquisition, announced on February 20, 2025, includes 250 mcg and 500 mcg strengths of the USFDA-approved tablets. Roflumilast is used for treating severe COPD associated with chronic bronchitis. The US market size for Roflumilast ranges from $32 million to $46 million. SPL plans to manufacture the tablets at its US site, expanding its portfolio into specialty distribution and the chronic bronchitis therapy area. The acquisition is funded through IPO proceeds.

20Feb 25

Senores Pharmaceuticals Expands Portfolio with Acquisition of Roflumilast ANDA

Senores Pharmaceuticals Limited has acquired the ANDA for Roflumilast tablets (250 mcg and 500 mcg) from Breckenridge Pharmaceutical, Inc. The acquisition, announced on February 20, 2025, aims to strengthen SPL's position in the US pharmaceutical market. Roflumilast is used for reducing COPD exacerbation risks. The US market for Roflumilast is valued at $32-46 million. Manufacturing will be done at SPL's US-based, USFDA-approved facility. The acquisition aligns with SPL's strategy to enter niche generic formulations markets and will be funded through IPO proceeds.